English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Low-molecular-weight heparin (LMWH) is commonly used to treat deep vein thrombosis. The dose is usually based on the patient’s body weight, and for some preparations the manufacturer recommends a daily maximum dose. Unlike the situation for unfractionated heparin, no effective antidote is available for LMWH overdose. Protamine sulphate neutralizes the anticoagulant effect of unfractionated heparin, but it is only partially effective against LMWH. Protamine sulphate is composed of polypeptides that bind heparin to form a stable, inactive complex that inhibits the anti–factor IIa effect of LMWH,1 but the effect on anti–factor Xa is only partial,2,3 reaching up to 74%.4 Despite the frequent use of LMWH, there are few descriptions of management strategies for LMWH overdoses. Furthermore, most case reports of LMWH overdose have involved patients who were relatively young.1-3,5-7 To the authors’ knowledge, the current article is the first report of LMWH overdose in a patient over 80 years of age.

Inadvertent Overdose of Low-Molecular- Weight Heparin in an Elderly Patient with Deep Vein Thrombosis and Acute Kidney Injury